



PLASMA MEDICINE FRONTIERS - ENERGY BASED TREATMENT MODALITIES FOR NEXT CENTURY- THE MEDICAL REVOLUTION HAS BEGUN

Clinical Research

Prof Dr Pradeep Kumar Radhakrishnan*

MS, MCh CTVS AIIMS, Postdoctoral fellow CTVS and ECMO, Chief Division of Cardiothoracic Surgery, GIMSR Gitam University. *Corresponding Author

Gayathri

Ananyajyothi Ambat

Student GIMSR, Gitam University.

Prof R M Rao

Gitam School of Science

Dr Nazeema Nazer

TMRI, MD D&V.

Dr Nihaz Nazer

MS, Mch CVTS, Jayadeva Institute

Prof Y A Nazer

Mch CTVS AIIMS, Director Travancore Heart Institute.

KEYWORDS

APPJ - atmospheric pressure plasma jet, RS- reactive species, DBD- dielectric barrier discharge, ECIS- electrical cell substrate impedance sensing, CAP – cold atmospheric plasma, LTP Low temperature plasma, PAW -Plasma activated water, PAM- Plasma activated media ,PAL Plasma activated liquid.

INTRODUCTION

Plasma medicine is fast emerging as an interdisciplinary research domain with vast clinical potential- essentially is a conglomeration of plasma physics, chemistry, biomedical science and engineering. The less dense forms of plasma at lower temperature are interrelated to auroras and stellar and solar winds.

DISCUSSION:

Plasma medicine is actually a conglomeration of plasma physics, clinical medicine and life sciences. This currently is a vivid example of interdisciplinary interaction for social benefit. An ionized gas which is charge neutral is plasma. One of its early recognised uses is sterilisation of biomaterial surfaces. Low temperature sources (LTP) that operate at atmospheric pressure can be used for medical applications. Burns would result with temperatures above 50 degree C. Resistive barrier discharges can be used for DC applications {1}. 50-60 Hz power sources are used. Here human body can serve as one of the electrodes. Bacterial inactivation {2}, skin disorders and cancer treatment {3} are early promising options. AC or pulsed power supply sources are used. Research and clinical studies currently use the following CE certified devices.

1. Atmospheric pressure plasma jet kINPen® MED (INP Greifswald/neoplas tools GmbH, Greifswald, Germany)
2. Dielectric barrier discharge source PlasmaDerm® VU-2010 (CINOGY GmbH plasma technology for health, Duderstadt, Germany)
3. SteriPlas (Adtec Ltd., London, United Kingdom)

APPJ- Atmospheric pressure plasma jets use gas to deliver plasma to tissues. Helium or Argon can be used for this purpose. Maximum reactive species generation occurs at the site where room air diffuses into the noble gas {4}. Di electric barrier discharges can be used to limit the current, but not in all devices. Other methods use a high voltage pin electrode at the centre of the quartz tube. Ionization waves mix with the ambient air prior to delivery. These have been termed as plasma bullets {5}. Direct contact with tissues delivers more reactive and charged species. Two planar jets with gas flow that when used simultaneously can be used to cover larger surfaces and simplifies usage {6}. Three major application fields include normothermic atmospheric pressure directed plasma therapy, plasma assisted modification of bio-relevant surfaces and plasma based sterilisation. Only normothermic atmospheric pressure types are suited for direct tissue application. The effects are due combination of electromagnetic radiation, reactive and charged species and primary radicals. The cells with greater oxidative stress are eliminated. Electroporation allows more radical species to enter the cells also. This knowledge can use nanoparticle for delivery of drugs by energy dependent and independent mechanisms of

endocytosis {12}. The additional component of systemic immune response stimulation also may be involved {13}. The accelerated endocytosis is via clathrin dependent membrane repair pathways, with lipid peroxidation and cell membrane damage {14}. APPJ treatment protects against hypoxia induced injury, glucose deprivation and attenuates hypoxia microenvironment using an electrical substrate impedance sensing system. Argon plasma coagulation finds role in surgical applications {7, 8}. A two-minute CAP treatment, for example, has been shown to be effective against a variety of bacteria including important skin and wound pathogens such as *Escherichia coli*, group A *Streptococcus*, Methicillin-resistant *Staphylococcus aureus* (MRSA), and *Pseudomonas aeruginosa*, suggesting positive effects of CAP on wound healing. It aids in chronic ulcer healing {9, 10}. Actinic keratosis, ichthyosis, scar management, acne rosacea, warts and androgenic alopecia (indirect plasma treatment) can be treated with plasma {11}. Role of nitric oxide released by plasma in wound healed was reported earlier by Russians {15} with augmented fibroblastic proliferation and enhanced phagocytosis. Cold plasma has found application in neuro differentiation and protection as well as anti cancer treatment like glioblastoma treatment {16}, selective differentiation of neuronal stem cells into neurons {17} and brain injuries, ischemia or infarction {18}. The potential use of CAP for cancer treatment has also been assessed in vitro and in vivo in several other nonskin cancer entities including breast cancer, pancreatic carcinomas, glioblastoma, colorectal carcinoma, and neuroblastomas {20, 21, 22, 23, 24}. Emerging new applications are noted in dental sciences too. Plasma activated liquids that have been used include water to make plasma activated water (PAW) and biological culture media to make plasma activated media (PAM).

CONCLUSIONS

Essentially multidisciplinary in its evolution plasma medicine heralds the way treatment modalities would evolve in future. Applications have grown and diversified into various subspecialties in medicine and newer mechanisms of action are being discovered leading to further enhanced applications. Direct molecular transportation of particles, that are species specific and with tissue propagation for desired medical or biological effects is an immediate reality that we are faced with. Energy based dry technologies for treatment should be envisaged for space travel as human race is on the verge of colonisation of other planets too.

REFERENCES

1. Laroussi, M., Alexeff, I., Richardson, J. P., and Dyer, F. F. "The Resistive Barrier Discharge", IEEE Trans. Plasma Sci. 30, pp. 158-159, (2002)
2. Laroussi, M., Richardson, J. P., and Dobbs, F. C. "Effects of Non-Equilibrium Atmospheric Pressure Plasmas on the Heterotrophic Pathways of Bacteria and on their Cell Morphology", Appl. Phys. Lett. 81, pp. 772-774, (2002)
3. Vandamme M., Robert E., Dozias S., Sobilo J., Lerondel S., Le Pape A., Pouvesle J.M., 2011. Response of human glioma U87 xenografted on mice to non thermal plasma

- treatment. *Plasma Medicine* 1:27-43
4. Norberg, Seth A.; Johnsen, Eric; Kushner, Mark J. (2015-01-01). "Formation of reactive oxygen and nitrogen species by repetitive negatively pulsed helium atmospheric pressure plasma jets propagating into humid air". *Plasma Sources Science and Technology*. 24 (3): 035026
 5. Lu, X (2012). "On atmospheric-pressure non-equilibrium plasma jets and plasma bullets". *Plasma Sources Science and Technology*. 21 (3): 034005
 6. Laroussi, M. "Low Temperature Plasma Jet for Biomedical Applications: A Review", *IEEE Trans. Plasma Sci.* 43, pp. 703-711, (2015)
 7. Zenker M, Argon plasma coagulation, *GMS Krankenhaushygiene Interdisziplinär* 2008; 3(1):Doc15 (20080311)
 8. Fridman G, Friedman G, Gutsol A, Shekter AB, Vasilets VN, Fridman A, *Applied Plasma Medicine, Plasma Process Polym* 5:503-533 (2008)
 9. Sibylla. "Retrieved 2021-02-02.Home". Terraplasma medical.
 10. Isbary, G.; Heinlin, J.; Shimizu, T.; Zimmermann, J.L.; Morfill, G.; Schmidt, H.-U.; Monetti, R.; Steffes, B.; Bunk, W.; Li, Y.; Klaempfl, T. (August 2012). "Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial: Argon plasma significantly decreases bacteria on wounds". *British Journal of Dermatology*. 167 (2): 404–410. doi: 01.1111/j.1365-2133.2012.10923.x. PMC 7161860. PMID 22385038.
 11. "Tolerability of Six Months Indirect Cold (Physical) Plasma Treatment of the Scalp for Hair Loss". *Journal of Drugs in Dermatology*
 12. He, Zhonglei; Liu, Kangze; Manaloto, Eline; Casey, Alan; Cribaro, George P.; Byrne, Hugh J.; Tian, Furong; Barcia, Carlos; Conway, Gillian E. (2018-03-28). "Cold Atmospheric Plasma Induces ATP-Dependent Endocytosis of Nanoparticles and Synergistic U373MG Cancer Cell Death". *Scientific Reports*. 8 (1): 5298. Bibcode:2018NatSR...8.5298H. doi:10.1038/s41598-018-23262-0. ISSN 2045-2322. PMC 5871835. PMID 29593309.
 13. He, Zhonglei; Liu, Kangze; Scally, Laurence; Manaloto, Eline; Gunes, Sebnem; Ng, Sing Wei; Maher, Marcus; Tiwari, Brijesh; Byrne, Hugh J.; Bourke, Paula; Tian, Furong; Cullen, Patrick J.; Curtin, James F. (24 April 2020). "Cold Atmospheric Plasma Stimulates Clathrin-Dependent Endocytosis to Repair Oxidised Membrane and Enhance Uptake of Nanomaterial in Glioblastoma Multiforme Cells". *Scientific Reports*. 10 (1): 6985. doi:10.1038/s41598-020-63732-y. PMC 7181794. PMID 32332819.
 14. Miller, Vandana; Lin, Abraham; Fridman, Alexander (2015-10-16). "Why Target Immune Cells for Plasma Treatment of Cancer". *Plasma Chemistry and Plasma Processing*. 36 (1): 259–268. doi:10.1007/s11090-015-9676-z. ISSN 0272-4324. S2CID 97696712.
 15. Shekhter AB, Kabisov RK, Pekshev AV, Kozlov NP, Perov YL. Experimental and clinical validation of plasmadynamic therapy of wounds with nitric oxide. *Bull Exp Biol Med*. 1998;126(8):829–34.
 16. Vermeylen S, De Waele J, Vanuytsel S, De Backer J, Van der Paal J, Ramakers M, et al. Cold atmospheric plasma treatment of melanoma and glioblastoma cancer cells. *Plasma Processes Polym*. 2016;13(12):1195–205
 17. Xiong Z, Zhao S, Mao X, Lu X, He G, Yang G, et al. Selective neuronal differentiation of neural stem cells induced by nanosecond microplasma agitation. *Stem Cell Res*. 2014;12(2):387–99.
 18. Dormanns K, Brown RG, David T. The role of nitric oxide in neurovascular coupling. *J Theor Biol*. 2016;394:1–17.
 19. Yan X, Meng ZZ, Ouyang JT, Qiao YJ, Li JX, Jia M, et al. Cytoprotective effects of atmospheric-pressure plasmas against hypoxia-induced neuronal injuries. *J Phys D Appl Phys*. 2018;51(8):085401
 20. R. M. Walk, J. A. Snyder, P. Srinivasan et al., "Cold atmospheric plasma for the ablative treatment of neuroblastoma," *Journal of Pediatric Surgery*, vol. 48, no. 1, pp. 67–73, 2013. View at: Publisher Site | Google Scholar
 21. M. Vandamme, E. Robert, S. Lerondel et al., "ROS implication in a new antitumor strategy based on non-thermal plasma," *International Journal of Cancer*, vol. 130, no. 9, pp. 2185–2194, 2012. View at: Publisher Site | Google Scholar
 22. N. Hattori, S. Yamada, K. Torii et al., "Effectiveness of plasma treatment on pancreatic cancer cells," *International Journal of Oncology*, vol. 47, no. 5, pp. 1655–1662, 2015. View at: Publisher Site | Google Scholar
 23. L. Brüllé, M. Vandamme, D. Riès et al., "Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model," *PLoS One*, vol. 7, no. 12, p. e52653, 2012. View at: Publisher Site | Google Scholar
 24. S. Mirpour, S. Piroozmand, N. Soleimani et al., "Utilizing the micron sized non-thermal atmospheric pressure plasma inside the animal body for the tumor treatment application," *Scientific Reports*, vol. 6, no. 1, 2016